Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Annexon (ANNX) granted a new non-executive employee an option to purchase 300,000 common shares under its 2022 Employment Inducement Award Plan.
The award was approved on November 14, 2026, under Nasdaq Listing Rule 5635(c)(4). The option has a $3.92 exercise price, equal to the stock’s November 13 closing price, and a ten-year term. It vests over four years: 25% on the first anniversary of the employment start date, followed by 1/48th of the underlying shares monthly, subject to continued service through each applicable vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.300,000-share employee option creates potential dilution at a $3.92 exercise price, with a ten-year term.
Key Figures
- Options granted
- 300,000 shares
- One new non-executive employee
- Exercise price
- $3.92 per share
- Equal to the November 13, 2026 closing price
- Option term
- 10 years
- Inducement option
- Vesting period
- 4 years
- Subject to continued service
- Initial vesting
- 25%
- On the first anniversary of the employment start date
- Subsequent vesting
- 1/48th of the underlying shares monthly
- After the first-anniversary vesting, subject to continued service
Historical Context
-
Granted options to six new employees under the 2022 plan, with four-year vesting.
-
Granted options to two new employees under the 2022 plan, with four-year vesting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on November 14, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 300,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to harmful inflammation, tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to millions of patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Annexon’s new employee inducement option?
Annexon granted an option to purchase 300,000 common shares at $3.92 per share, with a ten-year term. The exercise price equals the stock’s closing price on November 13, 2026.
When does Annexon’s new employee inducement option vest?
The option vests over four years, with 25% vesting on the first anniversary of the employment start date and an additional 1/48th monthly thereafter. Vesting requires continued service through each applicable vesting date.